Cite
HARVARD Citation
, . et al. (2017). Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study. Breast. pp. 115-121. [Online].